Vera Therapeutics Inc. has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) through the Accelerated Approval Program for atacicept, a potential treatment for adults with immunoglobulin A nephropathy (IgAN). Atacicept, which targets both BAFF and APRIL, received FDA Breakthrough Therapy Designation and demonstrated significant proteinuria reduction in the Phase 3 ORIGIN trial. If approved, it would be the first B cell modulator of its kind for IgAN, with potential FDA approval expected in 2026. No other organizations are mentioned as recipients of grant or regulatory approval in this announcement.